Los puntos clave no están disponibles para este artículo en este momento.
Randomized clinical trials have shown that sacubitril-valsartan reduces the risks of mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF), but patients with kidney failure requiring dialysis were excluded.
Le et al. (Tue,) studied this question.